Mesh Bio

Mesh Bio is a Singapore-based health deep-tech company that uses digital twin technology and predictive analytics to help clinicians detect and manage chronic diseases earlier. Its DARA platform automates health-screening report generation and risk stratification, while HealthVector Diabetes - approved as a Software as a Medical Device by Singapore's Health Sciences Authority - forecasts diabetes complications years before onset. Founded in 2018 by Andrew Wu and Arsen Batagov, the company serves more than 40 healthcare groups across Asia and has assessed over 300,000 patients.